Peixoto, Renata D <br/><br/>
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.  [electronic resource] 

 -  American journal of clinical oncology  Oct 2017 
 - 507-511 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1537-453X 
<br/><br/><label>Standard No.: </label>10.1097/COC.0000000000000193  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Albumins--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>British Columbia<br/>Deoxycytidine--administration & dosage<br/>Eligibility Determination--methods<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Palliative Care<br/>Pancreatic Neoplasms--drug therapy<br/>Gemcitabine